Furthermore, if a negative association between PSA levels and use of medications in the general population was caused primarily by the reduction in risk of developing the disease, the same effect could be significantly smaller or even entirely absent in the population of patients who were already diagnosed with cancer. This evidence concerns the gene KLK3 and cancer.